Cleveland Research analyst Steve Willoughby said recent OptimRX momentum gives him greater in his UnitedHealth above consensus FY17 earnings estimate of $9.16, versus consensus of $8.96.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here